Direction
Buy
Sell
Types
LMT Order
Price
QTY
Amount
--
ACUT ACCUSTEM SCIENCES INC
0.961+0.056+6.19%
Close
02/03 16:00 ET
High
1.100
Open
0.880
Turnover
10.12K
Low
0.800
Pre Close
0.905
Volume
11.10K
Intraday
5D
1D
1W
1M
1Q
1Y
Price Forecast
News
Comment
Cancer Diagnostics Maker Accustem Files for Nasdaq Uplisting, $11M Offering
AccuStem Sciences Announces Appointment of Sean McDonald to Board of Directors
LONDON and PHOENIX, Nov. 16, 2022 (GLOBE NEWSWIRE) -- AccuStem Sciences, Inc. (OTCQB: ACUT), a clinical stage diagnostics company dedicated to improving outcomes for patients with cancer, announced
AccuStem Announces Adjournment of Annual Meeting of Stockholders
LONDON and PHOENIX, Oct. 10, 2022 (GLOBE NEWSWIRE) -- AccuStem Sciences, Inc. (OTCQB:ACUT), a clinical stage diagnostics company dedicated to improving outcomes for patients with cancer, announced t
AccuStem Sciences Announces Issuance of US Patent for StemPrintER Test for Patients With Breast Cancer
LONDON and PHOENIX, Ariz., Sept. 13, 2022 (GLOBE NEWSWIRE) -- AccuStem Sciences, Inc. (OTCQB: ACUT), a clinical stage diagnostics company dedicated to improving outcomes for patients with cancer, an
AccuStem Sciences, Inc. Announces Chairman Purchase of Shares
LONDON and PHOENIX, Ariz., June 09, 2022 (GLOBE NEWSWIRE) -- AccuStem Sciences, Inc. (OTCQB: ACUT), a life sciences company dedicated to improving outcomes for patients with cancer, announced that i
AccuStem Sciences, Inc. Announces Chairman Purchase of Shares
LONDON and PHOENIX, April 28, 2022 (GLOBE NEWSWIRE) -- AccuStem Sciences, Inc. (OTCQB:ACUT), a life sciences company dedicated to improving outcomes for patients with cancer, announced that its Chairman of the Board, Mr. Gabriele Cerrone, has notified
4 Stocks Under $2 Insiders Are Aggressively Buying
US crude oil futures traded lower this morning on Thursday. Investors, meanwhile, focused on some notable insider trades. When insiders purchase or sell shares, it indicates their confidence or concer
AccuStem Sciences, Inc. Announces DTC Eligibility
LONDON and PHOENIX, April 14, 2022 (GLOBE NEWSWIRE) -- AccuStem Sciences, Inc. (OTCQB: ACUT), a life sciences company dedicated to improving outcomes for patients with cancer, is pleased to announce
AccuStem Announces Private Placement of Common Stock
LONDON and PHOENIX, April 05, 2022 (GLOBE NEWSWIRE) -- AccuStem Sciences, Inc. (OTC Pink: ACUT), a life sciences company dedicated to improving outcomes for patients with cancer, announced that it h
AccuStem Sciences, Inc. Announces DTC Eligibility
LONDON and PHOENIX, March 23, 2022 (GLOBE NEWSWIRE) -- AccuStem Sciences, Inc. (OTC Pink: ACUT), a life sciences company dedicated to improving outcomes for patients with cancer, is pleased to annou
Company Overview
More
AccuStem Sciences, Inc. engages in medical practice activities. It owns the breast cancer diagnostic StemPrintER and the SPARE genomics-based personalized medicine business. The StemPrintER is a multi-gene prognostic assay intended to predict the risk of recurrence of R+/HER2- breast cancer, and Spare, a derivative of StemPrintER, combines StemPrintER with two clinical markers. The firm anticipates this prognostic test to be used in conjunction with clinical evaluation to identify those patients at increased risk for early and late metastasis. The company was founded on June 5, 2020 and is headquartered in New York, NY.
CEO： --
Market： Pink Market
Paper Trade
More
Hot List
TradeSearchNews
SymbolLatest price%Chg
Loading...
Watchlist
No Stock Yet